Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

QEL 001

Drug Profile

QEL 001

Alternative Names: QEL-001

Latest Information Update: 15 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Quell Therapeutics
  • Class CAR-T cell therapies; Gene therapies
  • Mechanism of Action Immunologic cytotoxicity; Regulatory T-lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Liver transplant rejection

Most Recent Events

  • 09 Jun 2023 Quell Therapeutics plans a first-in-human clinical trial for Liver transplant rejection in 2023
  • 21 Jan 2022 Phase-I/II clinical trials in Liver transplant rejection (Treatment experienced) in United Kingdom (Parenteral) (NCT05234190)
  • 27 Oct 2021 UK Medicines and Healthcare products Regulatory Agency (MHRA) approves CTA application for QEL 001 in Liver transplant rejection
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top